Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019)

Pfaller, Michael A.; Mendes, Rodrigo E.; Streit, Jennifer M; Carvalhaes, Cecília G

doi:10.1016/j.diagmicrobio.2022.115804

Cited by 3 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our preliminary determinations, plasma concentrations of tedizolid in the two additional cases 20 h after the last administration were 0.6 and 0.9 µg/mL, a similar finding to those of cases 1 and 2, as described above. Although tedizolid is a novel oxazolidinone antibiotic prodrug used to treat infections caused by gram-positive organisms, such as methicillin-resistant S. aureus [ 1 – 3 ], the hospital director and attending physicians of patients with osteoarthritis in the cases decided to use this medicine for medical reasons (pretreatments, surgeries during hospitalization, etc.) before the outsourced test results in terms of methicillin resistance.…”

Section: Discussionmentioning

confidence: 99%

“…Tedizolid is a novel oxazolidinone antibiotic prodrug used to treat infections caused by gram-positive organisms such as methicillin-resistant Staphylococcus aureus [ 1 – 3 ]. Tedizolid phosphate is a promising antibiotic; however, its use is restricted by the adverse effects of long-term administration of 200 mg once daily [ 4 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection

Negishi,

Mitsumatsu,

Mitsumatsu

et al. 2023

J Pharm Health Care Sci

View full text Add to dashboard Cite

Background Tedizolid is a new oxazolidinone antibiotic with high potency for the treatment of infections caused by methicillin-resistant Staphylococcus aureus and other species. Case presentation Two patients with osteoarthritis (women aged 79 and 73 years, cases 1 and 2, respectively) infected with S. aureus were successfully treated with tedizolid after administration of 200 mg once daily via intravenous infusion. The synovial fluid and plasma concentrations of tedizolid during surgery in case 1 at day 7 were 2.1 and 1.6 µg/mL, respectively, yielding a ratio of synovial fluid/plasma of 130%. Those in case 2 at day 2 were 2.9 and 3.3 µg/mL, respectively, corresponding to a ratio of synovial fluid/plasma of 88%. Conclusions These results imply very similar concentrations of tedizolid in the synovial fluid and plasma of osteoarthritis patients with acute S. aureus infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection

Negishi,

Mitsumatsu,

Mitsumatsu

et al. 2023

J Pharm Health Care Sci

View full text Add to dashboard Cite

show abstract

“…At baseline, we also collected complete blood counts (CBC) and comprehensive metabolic panels (CMP), which included electrolytes and liver function tests. Susceptibility testing to tedizolid or linezolid was not routinely performed given that susceptibility among S. aureus and Gram-positive pathogens to these antibiotics is universal ( 13 ) and many isolates were no longer obtainable from the Clinical Microbiology Laboratory when participants consented to participation. Monofilament testing was done on all subjects to assess for previously undetected peripheral neuropathy.…”

Section: Methodsmentioning

confidence: 99%

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Miller,

Flores,

Launer

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

Bone and joint infections (BJIs) are common infections increasingly managed with oral therapy. However, there are limited safe oral options for many Gram-positive pathogens. In animal studies and short-term human use, tedizolid lacks the hematologic and neurologic toxicity of the other available oxazolidinone, linezolid. However, there are limited prospective safety data. We conducted an open-label, non-comparative trial of oral tedizolid for BJI treatment. Primary outcomes were safety and cure rate. Eligible patients had a BJI caused by documented or suspected Gram-positive pathogen, required 4–12 weeks of therapy, and did not have myelosuppression or peripheral/optic neuropathy. Subjects underwent weekly evaluation for cytopenias and neuropathy. We enrolled 44 subjects; five were lost to follow-up. Two subjects did not complete planned treatment because of rash ( n = 1) and urgent surgery ( n = 1). Of 37 patients with evaluable outcomes, 17 (46%) had hardware-associated infection, 13 (35%) had osteomyelitis, 5 (14%) had prosthetic joint infection, and 2 (5%) had other BJIs. Median (mean, range) treatment duration was 12 (10.1, 4–12) weeks. There were no cases of cytopenias or peripheral or optic neuropathy. Treatment cure occurred in 13 (35%); 19 (51%) required antibiotic continuation after 12 weeks of tedizolid related to retained hardware at the BJI site, and failure occurred in four (11%), two unlikely, one possibly, and one probably due to tedizolid. We found that oral tedizolid was well tolerated for prolonged BJI treatment without significant toxicity. Clinical failure rate was similar to that of other published BJI investigations. (This study has been registered at Clinicaltrials.gov under identifier NCT03009045.) IMPORTANCE Bone and joint infections are common infections with limited effective and safe oral options for Gram-positive infections. The largest prospective clinical trial of tedizolid therapy for bone and joint infections enrolled 44 patients and tested each in person weekly with detailed safety monitoring including tests for leukopenia, anemia, thrombocytopenia, peripheral neuropathy, and optic neuropathy for up to 12 weeks. Findings demonstrated tedizolid was generally well tolerated and there were no incident cases of cytopenias or neuropathy. Cure rates were similar to that in other bone and joint infection studies. In summary, oral tedizolid appears to be a well-tolerated oral option for Gram-positive bone and joint infections.

show abstract

Non- faecium non- faecalis enterococci: a review of clinical manifestations, virulence factors, and antimicrobial resistance

Mullally,

Fahriani,

Mowlaboccus

et al. 2024

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY Enterococci are a diverse group of Gram-positive bacteria that are typically found as commensals in humans, animals, and the environment. Occasionally, they may cause clinically relevant diseases such as endocarditis, septicemia, urinary tract infections, and wound infections. The majority of clinical infections in humans are caused by two species: Enterococcus faecium and Enterococcus faecalis . However, there is an increasing number of clinical infections caused by non- faecium non- faecalis (NFF) enterococci. Although NFF enterococcal species are often overlooked, studies have shown that they may harbor antimicrobial resistance (AMR) genes and virulence factors that are found in E. faecium and E. faecalis . In this review, we present an overview of the NFF enterococci with a particular focus on human clinical manifestations, epidemiology, virulence genes, and AMR genes.

show abstract

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019)

Cited by 3 publications

References 28 publications

Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection

Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Non- faecium non- faecalis enterococci: a review of clinical manifestations, virulence factors, and antimicrobial resistance

Contact Info

Product

Resources

About